Clinical Research For Patients
Hoag is committed to leading the way in state-of-the-art technologies and advanced treatment options. Part of this commitment includes groundbreaking clinical research with the goal of helping patients live longer, healthier lives.
Through carefully planned clinical trials, researchers evaluate the safety and effectiveness of new ways to diagnose, treat and prevent diseases or conditions. Treatments studied in clinical trials might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments.
Hoag is committed to maintaining the highest levels of objectivity in research, please review our Conflict of Interest Policy.
Institutional Biosafety Committee (IBC) Overview
Institutional Biosafety Committees (IBCs) help ensure that research involving recombinant or synthetic nucleic acid molecules and other potentially biohazardous materials is conducted safely and responsibly. These committees are a key part of protecting researchers, the public, and the environment, following the standards set by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.
Hoag partners with independent, accredited IBCs—such as Advarra IBC, WCG IBC, and Sabai IBC—to provide oversight for applicable research activities.
On March 28, 2025, the National Institutes of Health (NIH) issued a Guide Notice (NOT-OD-25-082) outlining new expectations for institutions conducting research subject to the NIH Guidelines. As part of these efforts to promote transparency, institutions must publicly post approved IBC meeting minutes for any meetings held on or after June 1, 2025.
These minutes will be posted here once approved and appropriately redacted to protect any confidential or proprietary information.
For more information, please visit the NIH Office of Science Policy.
View IBC Meeting Minutes
Contact Us at 949-764-4577